Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72

Stock Information for Abpro Holdings Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Abpro Holdings Inc

Abpro's Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference
Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers
Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives
Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager
Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager
Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025
Abpro Statement on the Departure of Former CEO Ian Chan

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.